| ATHS |
|
atherosclerosis susceptibility (lipoprotein associated)
|
|
|
0.551 |
0.769 |
| BTF3P11 |
|
basic transcription factor 3 pseudogene 11
|
|
|
0.519 |
0.731 |
| GTS |
|
Gilles de la Tourette syndrome
|
|
|
0.682 |
0.615 |
| HLA-DRB9 |
|
major histocompatibility complex, class II, DR beta 9 (pseudogene)
|
|
|
0.682 |
0.654 |
| MAA |
|
microphthalmia or anophthalmia and associated anomalies
|
|
|
0.666 |
0.577 |
| NM |
|
neutrophil migration
|
|
|
0.473 |
0.808 |
| OAP |
|
osteoarthrosis, precocious
|
|
|
0.792 |
0.192 |
| PTMAP4 |
|
prothymosin alpha pseudogene 4
|
|
|
0.638 |
0.731 |
| RMRP |
|
RNA component of mitochondrial RNA processing endoribonuclease
|
|
|
0.519 |
0.731 |
| TRBV20OR9-2 |
|
T cell receptor beta variable 20/OR9-2 (non-functional)
|
|
|
0.403 |
0.923 |
| CDR3 |
|
Cerebellar degeneration-related autoantigen-3
|
|
|
0.472 |
0.808 |
| MBL3P |
|
mannose-binding lectin family member 3, pseudogene
|
|
|
0.518 |
0.769 |
| MEG3 |
|
maternally expressed 3
|
|
|
0.471 |
0.846 |
| GAS5 |
|
growth arrest specific 5
|
|
|
0.497 |
0.808 |
| ZNRD1ASP |
|
zinc ribbon domain containing 1 antisense, pseudogene
|
|
|
0.691 |
0.538 |
| PWAR1 |
|
Prader Willi/Angelman region RNA 1
|
|
|
0.490 |
0.769 |
| DNAJB1P1 |
|
DnaJ heat shock protein family (Hsp40) member B1 pseudogene 1
|
|
|
0.650 |
0.654 |
| COPD |
|
Pulmonary disease, chronic obstructive, severe early-onset
|
|
|
0.456 |
0.885 |
| H19 |
|
H19 imprinted maternally expressed transcript
|
|
|
0.494 |
0.923 |
| NEAT1 |
|
nuclear paraspeckle assembly transcript 1
|
|
|
0.502 |
0.769 |
| MIF-AS1 |
|
MIF antisense RNA 1
|
|
|
0.663 |
0.577 |
| CYCSP51 |
|
CYCS pseudogene 51
|
|
|
0.751 |
0.423 |
| MALAT1 |
|
metastasis associated lung adenocarcinoma transcript 1
|
|
|
0.435 |
0.846 |
| MIRLET7B |
|
microRNA let-7b
|
|
|
0.493 |
0.769 |
| MIR106A |
|
microRNA 106a
|
|
|
0.524 |
0.846 |